1. Pink Sheet
  2. >>Geography
  3. >>Europe

Roche Upbeat On Recent Launches, Oncology And Actemra To Drive Growth Through Mid-Term

 
• By Michael Goodman

Roche presented a mixed sales picture across regions and products in a first quarter 2012 earnings call. Management highlighted a busy regulatory quarter with two new NME launches and five positive Phase III trials and filings, but also reported generic and competitive threats to key products.

Roche management described a quarter of moderate growth for the pharmaceuticals business driven primarily by sales in the U.S., and by a handful of key oncology products and the rheumatoid arthritis drug Actemra (tocilizumab). Quarterly growth of 2% was restrained by steep revenue declines in key off-patent or otherwise troubled franchises, including Tamiflu (oseltamivir), Boniva (ibandronate) and Cellcept (mycophenolate).

Management also provided color on how the company plans to position Lucentis (ranibizumab) in view of the recent launch of Regeneron Pharmaceuticals Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 
• By Neena Brizmohun

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

More from Geography

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.